Zevra Therapeutics (ZVRA) Revenue (2019 - 2026)

Zevra Therapeutics' Revenue history runs 8 years deep, the most recent figure standing at $36.2 million for Q1 2026.

• Quarterly Revenue rose 77.55% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.3 million (up 202.01% YoY) and the FY2025 annual result came in at $106.5 million, up 350.91% from the prior year.
• Revenue was $36.2 million for Q1 2026 at Zevra Therapeutics, up from $34.2 million in the prior quarter.
• Across five years, Revenue topped out at $36.2 million in Q1 2026 and bottomed at $1.3 million in Q2 2022.
• A 5-year average of $12.5 million and a median of $6.4 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue tumbled 89.55% — and 2025, when it soared 605.36%.
• Zevra Therapeutics' Revenue stood at $2.0 million in 2022, then jumped by 538.97% to $12.9 million in 2023, then fell by 7.03% to $12.0 million in 2024, then surged by 184.47% to $34.2 million in 2025, then climbed by 6.0% to $36.2 million in 2026.
• Business Quant data shows ZVRA's Revenue at $36.2 million in Q1 2026, $34.2 million in Q4 2025, and $26.1 million in Q3 2025.